BMS
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
February 5, 2026Research and Development BMS, Scottish Medicines Consortium, colorectal cancer, oncology
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination with Yervoy (ipilimumab), by the …
Elekta and BMS partner for digital treatment for melanoma
December 19, 2023Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …
BMS acquires Mirati Therapeutics for $4.8bn
October 9, 2023Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …
BMS shares new research and development plans at the company’s R&D day
September 15, 2023Research and Development BMS, Pharmacy, R&D, development, research
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, US, in order to discuss …
BMS follow-up data sees long-term survival for melanoma patients
May 24, 2021Sales and Marketing BMS, skin cancer
Bristol Myers Squibb (BMS) has announced follow-up data from their Phase III CheckMate-067 clinical trial, which demonstrated that 49% of …
NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer
November 5, 2020Sales and Marketing BMS, Cancer, NHS, NICE, opdivo
NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …
Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis
November 4, 2020Research and Development BMS, deucravacitinib, plaque psoriasis
Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …
Canadian approval for Reblozyl for transfusion-dependent anaemia in beta-thalassemia patients
September 29, 2020Manufacturing and Production, Sales and Marketing BMS, Canada, Reblozyl
Bristol Myers Squibb and Acceleron have managed to secure regulatory approval in Canada for Reblozyl (luspatercept) for the treatment of …
Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint
April 21, 2020Manufacturing and Production BMS, Bristol-Myers Squibb, Exelixis, bristol myers squibb
Bristol Myers Squibb and Exelixis have announced that the Phase 3 trial investigating the combination of Opdivo (nivolumab) and Cabometyx …
FDA approval for BMS and Acceleron’s Reblozyl to reduce red blood cell transfusion dependence
April 6, 2020Manufacturing and Production, Sales and Marketing BMS, FDA, Reblozyl, pharma
The FDA has given the regulatory thumbs-up in the US of Reblozyl (luspatercept-aamt), the “first and only erythroid maturation agent” …
BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer
February 3, 2020Sales and Marketing BMS, Cancer, Europe, Yervoy, lung cancer, opdivo
Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and …
EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma
September 25, 2019Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …
BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
September 5, 2019Research and Development BMS, glioblastoma multiforme, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …
Catalent to purchase Italy manufacturing facility from BMS
June 20, 2019Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, Cataletnt, pharma
Bristol-Myers Squibb has reached an agreement with Catalent for the latter to acquire its Anagni, Italy-based facility which specialises in …
Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
May 30, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
